Risk Factors Update Summary
- Potential loss of rights under the TCNT Agreement until mid-2026, impacting commercialization efforts.
- Addition of 4 new product candidates, including POCT testing devices and VELDONA candidates.
- Non-compliance with the Minimum Bid Price Requirement may lead to delisting from The Nasdaq Capital Market.
- Increase from 14 to 18 in the number of factors affecting operations as a public company.
- Dilution of all stockholders due to the issuance of additional capital stock in 2023.
- Dependence on third parties for manufacturing, with risks of delays, quality issues, and regulatory non-compliance.
- Potential adverse impact on business from health epidemics at clinical trial sites or other business operations.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1014763&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.